ECSP22005621A - Inhibidores tricíclicos de kars dependientes de akr1c3 - Google Patents
Inhibidores tricíclicos de kars dependientes de akr1c3Info
- Publication number
- ECSP22005621A ECSP22005621A ECSENADI20225621A ECDI202205621A ECSP22005621A EC SP22005621 A ECSP22005621 A EC SP22005621A EC SENADI20225621 A ECSENADI20225621 A EC SENADI20225621A EC DI202205621 A ECDI202205621 A EC DI202205621A EC SP22005621 A ECSP22005621 A EC SP22005621A
- Authority
- EC
- Ecuador
- Prior art keywords
- kars
- akr1c3
- dependent
- tricyclic inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 abstract 2
- 108091007984 KARS Proteins 0.000 abstract 2
- 102100035529 Lysine-tRNA ligase Human genes 0.000 abstract 2
- 108010065942 Prostaglandin-F synthase Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a nuevos compuestos tricíclicos que son inhibidores de KARS dependientes de AKR1C3, procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por un inhibidor de KARS dependiente de AKR1C3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881619P | 2019-08-01 | 2019-08-01 | |
| US202063009513P | 2020-04-14 | 2020-04-14 | |
| US202063033932P | 2020-06-03 | 2020-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22005621A true ECSP22005621A (es) | 2022-02-25 |
Family
ID=71994691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20225621A ECSP22005621A (es) | 2019-08-01 | 2022-01-24 | Inhibidores tricíclicos de kars dependientes de akr1c3 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US11970497B2 (es) |
| EP (2) | EP4013500B1 (es) |
| JP (1) | JP7008161B2 (es) |
| KR (1) | KR20220025845A (es) |
| CN (1) | CN114206870A (es) |
| AU (1) | AU2020309846B2 (es) |
| BR (1) | BR112022001308A2 (es) |
| CA (1) | CA3139940A1 (es) |
| CL (1) | CL2022000201A1 (es) |
| CO (1) | CO2022000370A2 (es) |
| CR (1) | CR20220031A (es) |
| CU (1) | CU24698B1 (es) |
| DK (1) | DK4013500T3 (es) |
| DO (1) | DOP2022000010A (es) |
| EC (1) | ECSP22005621A (es) |
| ES (1) | ES2969591T3 (es) |
| FI (1) | FI4013500T3 (es) |
| HR (1) | HRP20231734T1 (es) |
| HU (1) | HUE064882T2 (es) |
| IL (1) | IL287792A (es) |
| JO (1) | JOP20220020A1 (es) |
| LT (1) | LT4013500T (es) |
| MX (1) | MX2022000961A (es) |
| PE (1) | PE20220343A1 (es) |
| PL (1) | PL4013500T3 (es) |
| PT (1) | PT4013500T (es) |
| RS (1) | RS65068B1 (es) |
| SI (1) | SI4013500T1 (es) |
| TW (1) | TW202120507A (es) |
| UY (1) | UY38806A (es) |
| WO (1) | WO2021005586A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| UY38806A (es) | 2019-08-01 | 2021-02-26 | Novartis Ag | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos |
| JP2023540283A (ja) | 2020-09-02 | 2023-09-22 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ａｋｒ１ｃ３検出方法、並びにａｋｒ１ｃ３検出用診断キットおよびその使用 |
| CN113135878A (zh) * | 2021-04-09 | 2021-07-20 | 新沂市凯美斯特医药科技有限公司 | 一种以呋喃为原料合成3-氨基甲基四氢呋喃的方法 |
| AU2022270395A1 (en) * | 2021-05-07 | 2023-11-16 | Organon R&D Finland Ltd | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof |
| CN115403579A (zh) * | 2021-05-27 | 2022-11-29 | 上海拓界生物医药科技有限公司 | 一种新的螺环衍生物及其用途 |
| WO2023174319A1 (zh) * | 2022-03-15 | 2023-09-21 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| WO2023237080A1 (zh) * | 2022-06-10 | 2023-12-14 | 深圳艾欣达伟医药科技有限公司 | Akr1c3酶激活前药治疗癌症患者的方法 |
| WO2024023641A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention |
| WO2024023659A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Pharmaceutical compositions of tricyclic akr1c3 dependent kars inhibitor and methods for making same |
| WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048604A1 (en) * | 2004-08-20 | 2010-02-25 | Yee Dominic J | Ligands for Aldoketoreductases |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2013059245A1 (en) * | 2011-10-17 | 2013-04-25 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| EP3277380B1 (en) | 2015-03-10 | 2020-09-16 | Obi Pharma, Inc. | Dna alkylating agents |
| US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
| UY38806A (es) | 2019-08-01 | 2021-02-26 | Novartis Ag | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos |
-
2020
- 2020-07-27 UY UY0001038806A patent/UY38806A/es unknown
- 2020-07-30 TW TW109125732A patent/TW202120507A/zh unknown
- 2020-07-31 US US16/973,836 patent/US11970497B2/en active Active
- 2020-07-31 LT LTEPPCT/IB2020/057285T patent/LT4013500T/lt unknown
- 2020-07-31 CR CR20220031A patent/CR20220031A/es unknown
- 2020-07-31 MX MX2022000961A patent/MX2022000961A/es unknown
- 2020-07-31 FI FIEP20753456.1T patent/FI4013500T3/fi active
- 2020-07-31 WO PCT/IB2020/057285 patent/WO2021005586A1/en active Application Filing
- 2020-07-31 PL PL20753456.1T patent/PL4013500T3/pl unknown
- 2020-07-31 ES ES20753456T patent/ES2969591T3/es active Active
- 2020-07-31 CN CN202080053804.1A patent/CN114206870A/zh active Pending
- 2020-07-31 JP JP2021507653A patent/JP7008161B2/ja active Active
- 2020-07-31 PT PT207534561T patent/PT4013500T/pt unknown
- 2020-07-31 EP EP20753456.1A patent/EP4013500B1/en active Active
- 2020-07-31 JO JOP/2022/0020A patent/JOP20220020A1/ar unknown
- 2020-07-31 EP EP23195635.0A patent/EP4349839A2/en active Pending
- 2020-07-31 RS RS20240042A patent/RS65068B1/sr unknown
- 2020-07-31 HR HRP20231734TT patent/HRP20231734T1/hr unknown
- 2020-07-31 HU HUE20753456A patent/HUE064882T2/hu unknown
- 2020-07-31 KR KR1020227002658A patent/KR20220025845A/ko not_active Application Discontinuation
- 2020-07-31 PE PE2022000125A patent/PE20220343A1/es unknown
- 2020-07-31 DK DK20753456.1T patent/DK4013500T3/da active
- 2020-07-31 BR BR112022001308A patent/BR112022001308A2/pt unknown
- 2020-07-31 AU AU2020309846A patent/AU2020309846B2/en active Active
- 2020-07-31 CA CA3139940A patent/CA3139940A1/en active Pending
- 2020-07-31 CU CU2022000005A patent/CU24698B1/es unknown
- 2020-07-31 SI SI202030346T patent/SI4013500T1/sl unknown
-
2021
- 2021-11-02 IL IL287792A patent/IL287792A/en unknown
-
2022
- 2022-01-18 CO CONC2022/0000370A patent/CO2022000370A2/es unknown
- 2022-01-20 DO DO2022000010A patent/DOP2022000010A/es unknown
- 2022-01-24 EC ECSENADI20225621A patent/ECSP22005621A/es unknown
- 2022-01-25 CL CL2022000201A patent/CL2022000201A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| DOP2021000019A (es) | Inhibidores de inflamasoma nlrp3 | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
| ECSP21030482A (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CR20190379A (es) | Moduladores del receptor de estrógeno | |
| CL2023001220A1 (es) | Inhibidores de interleucina-17 | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| ECSP21010874A (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| UY38217A (es) | Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona |